Design, synthesis and anticancer activity of shikonin and alkannin derivatives with different substituents on the naphthazarin scaffold

Abstract

Based on the asymmetric reduction of alkannin ketone derivative 4 by diisopinocampheylchloroborane(DIP-Cl), a series of shikonin and alkannin derivatives was designed, synthesized and their anticancer activities against various kinds of cell lines were evaluated. The in vitro biological experiments demonstrated that compound S-10, a 5,8-O-dimethyl-1,4-dioxime alkannin derivative, not only displayed excellent antiproliferative activity against cancer cells, but also exhibited low toxicity towards normal cells. It could induce HCT-116 cell apoptosis, but had no impact on the cell cycle. The underlying anticancer mechanism of S-10 is most likely different from other shikonin and alkannin derivatives.

Keywords

Shikonin and alkannin oxime derivative / Asymmetric reduction / Anticancer / Apoptosis / Cell cycle

References

[1] An J., Li J. P., Chen W. X., Yang C. X., Hu F. D., Wang C. M. Chem. Res. Chinese Universities, 2013, 29(4): 798.

[2] Zhao X. D., Jin Y. C., Zeng X. H., Zhang B. L., Zhang Y. F. Chem. Res. Chinese Universities, 2011, 27(4): 562.

[3] Miller M. G., Rodgers A., Cohen G. M. Biochem. Pharmacol., 1986, 35: 1177.

[4] Wu H., Huang Z., Bu X., Shen Y., Zhang Z., Xie B., Liu Z., Gu L., Chan A. Eur. J. Med. Chem., 2005, 40: 1341.

[5] Zhou W., Peng Y., Li S. Eur. J. Med. Chem., 2010, 45: 6005.

[6] Zhou W., Zhang X., Xiao L., Ding J., Liu Q., Li S. Eur. J. Med. Chem., 2011, 46: 3420.

[7] Wang R., Zhang X., Song H., Zhou S., Li S. Bioorg. Med. Chem. Lett., 2014, 24: 4304.

[8] Armarego W. L. F., Chai C. L. L. Purification of Laboratory Chemicals( Seventh Edition), 2013, 5.

[9] Zhao L., Xu D., Zhou W., Li S. Lett. Org. Chem., 2008, 5: 234.

[10] Li S., Zhao L. Antineoplastic Alkanna tinctoria Ketoximes Derivatives, 2010.

[11] American Type Culture Collection, http://www.atcc.org

[12] Yang H. L., Xu G. X., Bao M. Y., Zhang D. D., Li Z. W., Pei Y. Z. Chem. J. Chinese Universities, 2014, 35(12): 2584.

[13] So J. Y., Lin J. J., Wahler J., Liby K. T., Sporn M. B., Suh N., PLoS ONE, 2014, 9, e107616.

[14] Huang W., Wan C., Luo Q., Huang Z., Luo Q. Int. J. Mol. Sci., 2014, 15: 3432.

[15] Shin S. Y., Hyun J., Yu J. R., Lim Y., Lee Y. H. Toxicol. Appl. Pharm., 2011, 254: 288.

[16] Zheng X., Wang R., Zhu M., Jing Z., Li S. J. Chem. Res., 2011, 35: 669.

[17] Couladouros E. A., Plyta Z. F., Strongilos A. T., Papageorgiou V. P. Tetrahedron Lett., 1997, 38: 7263.

[18] Brown H. C., Ramachandran P. V. Accounts, Chem. Res., 1992, 25: 16.

[19] Ramachandran P. V., Brown H. C. Reductions in Organic Synthesis, 1996, Washington DC: American Chemical Society 84.

[20] Xu Y., Cui J., Wang R., Li S. J. Shenyang Pharm. University, 2014, 31(6): 440.

[21] Wang R., Zhou S., Jiang H., Zheng X., Zhou W., Li S. Eur. J. Org. Chem., 2012, 2012(7): 1373.

[22] Zhang X., Wang R., Zhou W., Xiao S., Meng Q., Li S. AAPS Pharm. Sci. Tech., 2015, 16(2): 259.

[23] Katz D., Ito E., Lau K. S., Mocanu J. D., Bastianutto C., Schimmer A. D., Liu F. F. Biotechniques, 2008, 44: 9.

[24] Clarke M. F., Dick J. E., Dirks P. B., Eaves C. J., Jamieson C. H. M., Jones D. L., Visvader J., Weissman I. L., Wahl G. M. Cancer Res., 2006, 66: 9339.